VRAX (Virax Biolabs Group) EV-to-EBIT : 0.38 (As of May. 14, 2025)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Virax Biolabs Group's Enterprise Value is $-2.55 Mil. Virax Biolabs Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-6.68 Mil. Therefore, Virax Biolabs Group's EV-to-EBIT for today is 0.38.

The historical rank and industry rank for Virax Biolabs Group's EV-to-EBIT or its related term are showing as below:

VRAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -192.84 Med: 0.19 Max: 1.59
Current: 0.38

During the past 5 years, the highest EV-to-EBIT of Virax Biolabs Group was 1.59. The lowest was -192.84. And the median was 0.19.

VRAX's EV-to-EBIT is ranked better than
80.71% of 477 companies
in the Biotechnology industry
Industry Median: 6.72 vs VRAX: 0.38

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Virax Biolabs Group's Enterprise Value for the quarter that ended in Sep. 2024 was $1.29 Mil. Virax Biolabs Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-6.68 Mil. Virax Biolabs Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 was -517.73%.

Virax Biolabs Group EV-to-EBIT Historical Data

The historical data trend for Virax Biolabs Group's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group EV-to-EBIT Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

Mar24

EV-to-EBIT

-0.25

0.26

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
EV-to-EBIT	Get a 7-Day Free Trial					-	-0.25	-	0.26	-

Competitive Comparison of Virax Biolabs Group's EV-to-EBIT

For the Biotechnology subindustry, Virax Biolabs Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's EV-to-EBIT falls into.

Save Embed

;

Save Embed

;

Virax Biolabs Group EV-to-EBIT Calculation

Virax Biolabs Group's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	-2.553	/	-6.676
	=	0.38

Virax Biolabs Group's current Enterprise Value is $-2.55 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-6.68 Mil.

Virax Biolabs Group (NAS:VRAX) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Virax Biolabs Group's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Sep. 2024 )	=	EBIT	/	Enterprise Value (Q: Sep. 2024 )
	=	-6.676	/	1.28948
	=	-517.73 %

Virax Biolabs Group's Enterprise Value for the quarter that ended in Sep. 2024 was $1.29 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Virax Biolabs Group's EBIT for the trailing twelve months (TTM) ended in Sep. 2024 was $-6.68 Mil.

Virax Biolabs Group EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

Bo’Ness Road Newhouse, BioCity Glasgow, London, GBR, ML1 5UH

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.